Table 2.

AUC from baseline to 2 hours post-dose for the change from baseline in throat soreness

	AMC/DCBA Warm lozenge	AMC/DCBA Cool lozenge	Unflavoured, non-medicated lozenge
ITT Set
N	77	74	74
Mean ± SD	-1.83 ± 1.50	-2.07 ± 1.47	-1.00 ± 1.61
LS meana	-1.78	-2.06	-0.98
Parameter estimates	LS meanb	95% CI	P-value
AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenge	-0.80	-1.27,-0.33	0.001 **
AMC/DCBA Cool lozenge - unflavoured non­medicated lozenge	-1.08	-1.56,-0.60	<0.0001 ***
PP Set
N	75	64	64
Mean ± SD	-1.87 ± 1.50	-2.16 ± 1.50	-1.25 ± 1.39
LS meana	-1.83	-2.09	-1.11
Parameter estimates	LS meanb	95% CI	P-value
AMC/DCBA Warm lozenge - unflavoured, non­medicated lozenge	-0.72	-1.21,-0.23	0.004 **
AMC/DCBA Cool lozenge - unflavoured, non­medicated lozenge	-0.98	-1.48,-0.47	0.0002 ***

a Estimated from ANCOVA model with factors for treatment and centre and a covariate for baseline throat soreness.

b A negative difference favours the first treatment against second treatment.

** Significantly different compared with the unflavoured, non-medicated lozenge at the 1% level.

*** Significantly different compared with the unflavoured, non-medicated lozenge at the 0.1% level.

CI, confidence interval; LS, least-squares; SD, standard deviation; ITT, intention-to-treat; PP, per-protocol.

Throat soreness measured on an 11-point scale where 0 = Not sore, 10 = Very sore